Roche Quarterly Sales Held Back by Blockbuster Eye Drug

Bloomberg.com·2d ago

This story is reported by Bloomberg.com. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

The top 20 pharma companies by 2025 revenue

Fierce Pharma·Apr 20

2

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

BioPharma Dive·Feb 20

3

Roche Raises Forecast as New Medicines Fuel Growth

Bloomberg.com·Oct 23

4

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

BioPharma Dive·Jan 12

5

Regeneron's blockbuster eye drug posts weaker sales due to inventory impact

Reuters·May 2

6

Roche and Regeneron Square Off in Lucrative Eye Disease Market

BioSpace·Sep 4

7

All eyes on high-dose Eylea as Roche's new Vabysmo makes moderate impact in blockbuster eye disease market

Fierce Pharma·Sep 7

8

Regeneron allays competition fears for 'gold standard' eye drug, shares rise

Reuters·Aug 3